Watchlist Price Alert

Arcus Biosciences Inc. (RCUS)

NYSE: RCUS · Real-Time Price · USD

8.57

0.21 (2.51%)

At close: Jul 02, 2025, 3:59 PM

8.85

3.21%

After-hours: Jul 02, 2025, 06:00 PM EDT

2.51% (1D)

Bid	8.55
Market Cap	907.96M
Revenue (ttm)	141M
Net Income (ttm)	-391M
EPS (ttm)	-4.23
PE Ratio (ttm)	-2.03
Forward PE	-1.81
Analyst	Buy

Ask	8.85
Volume	549,447
Avg. Volume (20D)	1,262,686
Open	8.39
Previous Close	8.36
Day's Range	8.37 - 8.80
52-Week Range	6.50 - 18.98
Beta	0.83

About RCUS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RCUS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RCUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Arcus Biosciences Inc. is scheduled to release its earnings on Aug 7, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-1.35%

Arcus Biosciences shares are trading lower after t... Unlock content with Pro Subscription

4 months ago

-16.34%

Arcus Biosciences shares are trading lower after the company announced a $150 million stock offering.

News

1 week ago · businesswire.com

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

3 weeks ago · https://www.defenseworld.net

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,872 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.3% during the 4th quarter, according to the...

1 month ago · businesswire.com

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

1 month ago · seekingalpha.com

Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript

Arcus Biosciences, Inc. (NYSE:RCUS ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Pia Eaves - VP, IR Terry Rosen - CEO Richard Markus - CMO Jennifer Jarrett - COO Bob G...

1 month ago · zacks.com

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.05 per share a year ago.

2 months ago · businesswire.com

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...

3 months ago · seekingalpha.com

Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts

Arcus Biosciences presents a high-risk speculation with significant upcoming catalysts, despite recent stock declines and Gilead's exit from the ARC-10 trial. Gilead's continued investment and board p...